# Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema

> **NCT01832896** · PHASE2 · WITHDRAWN · sponsor: **NYU Langone Health**

## Conditions studied

- Hereditary Angioedema Types I and II

## Interventions

- **DRUG:** Ecallantide subcutaneous dosing

## Key facts

- **NCT ID:** NCT01832896
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-08
- **Primary completion:** 2017-07
- **Final completion:** 2017-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI indicated departure from institution, inability to complete study.
- **Last updated:** 2023-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01832896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01832896, "Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01832896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*